Baijin Life Science (HKG:1466) said it expects to post a net profit of about HK$2.5 million for the six months ended Sept. 30, compared with a loss of roughly HK$1.9 million a year earlier, according to a Tuesday Hong Kong bourse filing.

The improvement for the fiscal first half is mainly driven by a gain from the change in fair value of a convertible bond, partly offset by lower gross profit, the company said.

Full interim results are scheduled for release on Nov. 27.